Remarkable Recovery of Low-Risk Myelodysplastic Syndrome, A case of complete Hematologic Remission .
DOI:
https://doi.org/10.37375/susj.v15i2.3720Keywords:
myelodysplastic syndrome, pancytopenia, Immunosuppressive therapy, , cyclosporine and eltrombopagAbstract
Background: Pediatric myelodysplastic syndrome is rare and typically presents with unexplained cytopenias. We report a case of a previously healthy 14-year-old male presenting with severe pancytopenia diagnosed as low-risk MDS ,who showed a marked hematologic response to immunosuppressive therapy with cyclosporine and eltrombopag.
Case Presentation: The patient presented with dizziness and severe pancytopenia (anemia , Leukopenia, thrombocytopenia ). Initial workup excluded nutritional deficiencies, viral etiologies, and hemolysis. Bone marrow biopsy revealed hypocellular marrow with rare megakaryocytes and blasts at 2%, consistent with Myelodysplastic sydrome. Management included Intensive care unite admission, transfusions, corticosteroids, cyclosporine, and eltrombopag. Substantial hematologic improvement was seen within three months.
Conclusion: Immunosuppressive therapy resulted in full hematologic recovery and normalization of bone marrow function. This case underscores the importance of early recognition and prompt treatment of pediatric myelodysplastic syndrome .
References
Brodsky RA et al .(2014) Immune pathophysiology of bonemarrow failure. Blood. 2014.
Daniel S et al. (2010) Pediatric myelodysplastic syndrome with germline RRAS mutation: expanding the phenotype of RASopathies. Journal of Pediatric Hematology/Oncology
doi : 43 (4), e517-e520, 2021
Fenaux P et al(2010) .Efficacy of azacitidine in the treatment of high risk myloplastic syndrome , 2010 .
Franco L et al .(2018) How I treat myelodysplastic syndromes of childhood, Blood, The Journal of the American Society of Hematology doi : 131 (13), 1406-1414, 2018.
KantarjianH .(2010) Myelodysplastic Syndromes Overview. Lancet. 2021.
Malcovati Let al (2013) , Diagnosis and treatment of primary myleodysplastic syndrome in adults , blood ,2013 .
Martina R et al(2022) . The International Consensus Classifcation (ICC) of hematologic neoplasms with germline predisposition, pediatric myelodysplastic 2022
Scheinberg P & Young NS.et al (2012) How I treat acquired aplastic anemia. Blood. 2012.
Townsley DM et al(2017). Eltrombopag Added to Standard Immunosuppression. N Engl J Med. 2017.
-Yoshida N et al. (2020)Pediatric MDS: Biology and Treatment. Int J Hematol. 202011-
Zaina I et al.(2024), Pediatric Myelodysplastic Syndrome: Updated Classifications and Current Diagnosis and Treatment, https://doi.org/10.5858/arpa.2024-0164-RA, 2025 .
